{
    "id": 29178,
    "fullName": "BRAF R239Q",
    "impact": "missense",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "BRAF R239Q lies within the phorbol-ester/DAG-type zinc finger region of the Braf protein (UniProt.org). R239Q has been identified in the scientific literature (PMID: 29903896), but has not been biochemically characterized and therefore, its effect on Braf protein function is unknown (PubMed, Mar 2020).",
            "references": [
                {
                    "id": 285,
                    "pubMedId": null,
                    "title": null,
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed"
                },
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                },
                {
                    "id": 13465,
                    "pubMedId": 29903896,
                    "title": "Dual MAPK Inhibition Is an Effective Therapeutic Strategy for a Subset of Class II BRAF Mutant Melanomas.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29903896"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 673,
        "geneSymbol": "BRAF",
        "terms": [
            "BRAF",
            "B-raf",
            "B-RAF1",
            "BRAF1",
            "NS7",
            "RAFB1"
        ]
    },
    "variant": "R239Q",
    "createDate": "01/08/2019",
    "updateDate": "03/29/2020",
    "referenceTranscriptCoordinates": {
        "id": 177843,
        "transcript": "NM_004333",
        "gDna": "chr7:g.140801556C>T",
        "cDna": "c.716G>A",
        "protein": "p.R239Q",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 15612,
            "approvalStatus": "Preclinical - Pdx & cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of Braftovi (encorafenib) to treatment with Mektovi (binimetinib) increased growth inhibition in patient-derived melanoma cells harboring BRAF L597S, as well as BRAF R239Q, in culture, and resulted in tumor shrinkage in 67% of tumors, increased inhibition of ERK phosphorylation, and increased tumor growth delay compared to either agent alone in a patient-derived xenograft (PDX) model (PMID: 29903896).",
            "molecularProfile": {
                "id": 31114,
                "profileName": "BRAF R239Q BRAF L597S"
            },
            "therapy": {
                "id": 1100,
                "therapyName": "Binimetinib + Encorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 13465,
                    "pubMedId": 29903896,
                    "title": "Dual MAPK Inhibition Is an Effective Therapeutic Strategy for a Subset of Class II BRAF Mutant Melanomas.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29903896"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15614,
            "approvalStatus": "Preclinical - Pdx & cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Mektovi (binimetinib) inhibited growth of patient-derived melanoma cells harboring BRAF L597S, as well as BRAF R239Q, in culture, and induced tumor shrinkage in 25% (3/12) of tumors and delayed tumor growth in a patient-derived xenograft (PDX) model (PMID: 29903896).",
            "molecularProfile": {
                "id": 31114,
                "profileName": "BRAF R239Q BRAF L597S"
            },
            "therapy": {
                "id": 807,
                "therapyName": "Binimetinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 13465,
                    "pubMedId": 29903896,
                    "title": "Dual MAPK Inhibition Is an Effective Therapeutic Strategy for a Subset of Class II BRAF Mutant Melanomas.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29903896"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15613,
            "approvalStatus": "Preclinical - Pdx & cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Braftovi (encorafenib) inhibited ERK activation and proliferation of patient-derived melanoma cells harboring BRAF L597S, as well as BRAF R239Q, in culture, and delayed tumor growth and induced shrinkage in 8% (1/12) of tumors in a melanoma patient-derived xenograft (PDX) model (PMID: 29903896).",
            "molecularProfile": {
                "id": 31114,
                "profileName": "BRAF R239Q BRAF L597S"
            },
            "therapy": {
                "id": 796,
                "therapyName": "Encorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 13465,
                    "pubMedId": 29903896,
                    "title": "Dual MAPK Inhibition Is an Effective Therapeutic Strategy for a Subset of Class II BRAF Mutant Melanomas.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29903896"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15616,
            "approvalStatus": "Preclinical - Pdx & cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of Tafinlar (dabrafenib) to treatment with Mekinist (trametinib) resulted in increased growth inhibition in a patient-derived melanoma cell line harboring BRAF L597S, as well as well as BRAF R239Q, in culture, and resulted in tumor shrinkage in 100% (13/13) of subcutaneous tumors, and decreased growth of intracranial tumors in a patient-derived xenograft (PDX) model (PMID: 29903896).",
            "molecularProfile": {
                "id": 31114,
                "profileName": "BRAF R239Q BRAF L597S"
            },
            "therapy": {
                "id": 1066,
                "therapyName": "Dabrafenib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 13465,
                    "pubMedId": 29903896,
                    "title": "Dual MAPK Inhibition Is an Effective Therapeutic Strategy for a Subset of Class II BRAF Mutant Melanomas.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29903896"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 31114,
            "profileName": "BRAF R239Q BRAF L597S",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31115,
            "profileName": "BRAF R239Q",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 177840,
            "transcript": "XM_005250045",
            "gDna": "chr7:g.140801556C>T",
            "cDna": "c.716G>A",
            "protein": "p.R239Q",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 177842,
            "transcript": "XM_017012558",
            "gDna": "chr7:g.140801556C>T",
            "cDna": "c.716G>A",
            "protein": "p.R239Q",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 177841,
            "transcript": "XM_017012559",
            "gDna": "chr7:g.140801556C>T",
            "cDna": "c.716G>A",
            "protein": "p.R239Q",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 177843,
            "transcript": "NM_004333",
            "gDna": "chr7:g.140801556C>T",
            "cDna": "c.716G>A",
            "protein": "p.R239Q",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}